| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| ANVSAnnovis Bio, Inc. | 84.81M | 3.20 | -0.00 | -189.15% | ||||
| CLNNClene Inc. | 60.19M | 5.11 | -0.90 | -47.71% | -142.5% | -17.38% | ||
| ABOSAcumen Pharmaceuticals, Inc. | 112.67M | 1.86 | -1.09 | -143.12% | 0.16 | |||
| BHVNBiohaven Ltd. | 1.58B | 11.92 | -1.28 | -198.83% | 0.09 | |||
| IKTInhibikase Therapeutics, Inc. | 200.09M | 1.65 | -1.42 | -100% | -65.37% | 0.00 | ||
| ALECAlector, Inc. | 198.66M | 1.82 | -1.48 | 3.6% | -156.03% | -186.68% | 0.34 | |
| CGTXCognition Therapeutics, Inc. | 121.82M | 1.38 | -1.62 | -76.61% | 0.04 | |||
| ATHEAlterity Therapeutics Limited | 60M | 3.31 | -2.90 | 35.32% | -330.63% | -73.75% | 0.00 |
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - |
| Gross Profit Growth % | - | - | - | - |
| Operating Expenses | 12.62M | 16.13M | 8.31M | 6.81M |
| OpEx % of Revenue | - | - | - | - |
| Selling, General & Admin | 8.28M | 9.81M | 6.34M | 5.21M |
| SG&A % of Revenue | - | - | - | - |
| Research & Development | 4.34M | 6.32M | 1.97M | 1.6M |
| R&D % of Revenue | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 |
| Operating Income | 0 | 0 | 0 | 0 |
| Operating Margin % | - | - | - | - |
| Operating Income Growth % | - | - | - | - |
| EBITDA | -12.61M | -16.13M | -8.31M | -6.81M |
| EBITDA Margin % | - | - | - | - |
| EBITDA Growth % | - | -0.28% | 0.48% | 0.18% |
| D&A (Non-Cash Add-back) | 4.97K | 5.71K | 6.35K | 5.58K |
| EBIT | -12.62M | -16.13M | -8.31M | -6.81M |
| Net Interest Income | 7.11K | 335.04K | 1.65M | 1.28M |
| Interest Income | 7.11K | 335.04K | 1.65M | 1.28M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income/Expense | -12.61M | -5.57M | -6.04M | -12.77M |
| Pretax Income | -12.61M | -5.57M | -6.04M | -12.77M |
| Pretax Margin % | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% |
| Net Income | -12.61M | -5.57M | -6.04M | -12.77M |
| Net Margin % | - | - | - | - |
| Net Income Growth % | - | 0.56% | -0.08% | -1.11% |
| Net Income (Continuing) | -12.61M | -5.57M | -6.04M | -12.77M |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -62.75 | -20.25 | -29.56 | 0.00 |
| EPS Growth % | - | 0.68% | -0.46% | 1% |
| EPS (Basic) | -62.75 | -20.25 | -29.56 | 0.00 |
| Diluted Shares Outstanding | 200.6K | 279.57K | 466.1K | 0 |
| Basic Shares Outstanding | 200.6K | 279.57K | 466.1K | 0 |
| Dividend Payout Ratio | - | - | - | - |
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Total Current Assets | 35.5M | 38.59M | 30.53M | 17.72M |
| Cash & Short-Term Investments | 34.21M | 37.48M | 30.1M | 17.66M |
| Cash Only | 34.21M | 37.48M | 28.66M | 17.66M |
| Short-Term Investments | 0 | 0 | 1.44M | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - |
| Other Current Assets | 879.87K | 739.47K | 57.68K | 64.63K |
| Total Non-Current Assets | 20.45K | 22.14K | 580.91K | 12.93K |
| Property, Plant & Equipment | 20.45K | 22.14K | 18.5K | 12.93K |
| Fixed Asset Turnover | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 562.4K | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 |
| Total Assets | 35.52M | 38.61M | 31.11M | 17.73M |
| Asset Turnover | - | - | - | - |
| Asset Growth % | - | 0.09% | -0.19% | -0.43% |
| Total Current Liabilities | 1.99M | 1.31M | 4.28M | 1.01M |
| Accounts Payable | 1.3M | 660.21K | 444.63K | 317.29K |
| Days Payables Outstanding | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 |
| Current Ratio | 17.80x | 29.39x | 7.14x | 17.47x |
| Quick Ratio | 17.80x | 29.39x | 7.14x | 17.47x |
| Cash Conversion Cycle | - | - | - | - |
| Total Non-Current Liabilities | 0 | 1.88M | 1.25M | 9.94M |
| Long-Term Debt | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 1.88M | 1.25M | 9.94M |
| Total Liabilities | 1.99M | 3.19M | 5.53M | 10.96M |
| Total Debt | 0 | 0 | 0 | 0 |
| Net Debt | -34.21M | -37.48M | -28.66M | -17.66M |
| Debt / Equity | - | - | - | - |
| Debt / EBITDA | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - |
| Interest Coverage | - | - | - | - |
| Total Equity | 33.53M | 35.41M | 25.58M | 6.78M |
| Equity Growth % | - | 0.06% | -0.28% | -0.74% |
| Book Value per Share | 167.14 | 126.68 | 54.89 | - |
| Total Shareholders' Equity | 33.53M | 35.41M | 25.58M | 6.78M |
| Common Stock | 674 | 728 | 96 | 137 |
| Retained Earnings | -14.14M | -19.83M | -33.61M | -47.17M |
| Treasury Stock | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 902 | 5.7K |
| Minority Interest | 0 | 0 | 0 | 0 |
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Cash from Operations | -8.71M | -11.21M | -5.17M | -4.88M |
| Operating CF Margin % | - | - | - | - |
| Operating CF Growth % | - | -0.29% | 0.54% | 0.06% |
| Net Income | -12.61M | -5.57M | -6.04M | -12.77M |
| Depreciation & Amortization | 4.97K | 5.71K | 6.35K | 5.58K |
| Stock-Based Compensation | 3.28M | 3.74M | 1.01M | 25.41K |
| Deferred Taxes | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 587.19K | -8.77M | -508.4K | 7.35M |
| Working Capital Changes | 25.93K | -614.95K | 358.02K | 501.87K |
| Change in Receivables | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 |
| Change in Payables | 36.17K | -636.3K | -215.57K | -127.35K |
| Cash from Investing | -3.2K | -7.41K | -2M | -1M |
| Capital Expenditures | -3.2K | -7.41K | -2.71K | 0 |
| CapEx % of Revenue | - | - | - | - |
| Acquisitions | - | - | - | - |
| Investments | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 |
| Cash from Financing | 37.13M | 14.48M | -1.64M | -5.12M |
| Debt Issued (Net) | - | - | - | - |
| Equity Issued (Net) | - | - | - | - |
| Dividends Paid | 0 | 0 | -641.07K | -950.92K |
| Share Repurchases | - | - | - | - |
| Other Financing | 13.35M | 553.15K | 0 | 0 |
| Net Change in Cash | - | - | - | - |
| Free Cash Flow | -8.71M | -11.22M | -5.18M | -4.88M |
| FCF Margin % | - | - | - | - |
| FCF Growth % | - | -0.29% | 0.54% | 0.06% |
| FCF per Share | -43.44 | -40.13 | -11.10 | - |
| FCF Conversion (FCF/Net Income) | 0.69x | 2.01x | 0.86x | 0.38x |
| Interest Paid | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 |
| Metric | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Return on Equity (ROE) | -37.61% | -16.17% | -19.8% | -78.91% |
| FCF Conversion | 0.69x | 2.01x | 0.86x | 0.38x |
TAO Synergies Inc. (TAOX) reported $0.2M in revenue for fiscal year 2024.
TAO Synergies Inc. (TAOX) grew revenue by 0.0% over the past year. Growth has been modest.
TAO Synergies Inc. (TAOX) reported a net loss of $26.6M for fiscal year 2024.
TAO Synergies Inc. (TAOX) has a return on equity (ROE) of -78.9%. Negative ROE indicates the company is unprofitable.
TAO Synergies Inc. (TAOX) had negative free cash flow of $5.1M in fiscal year 2024, likely due to heavy capital investments.